Terug

Pediatric Tumor Immunology and HCT: Group Nierkens

Pediatric Tumor Immunology and HCT: Group Nierkens

Pediatric Immunology and HCT

About uitklapper, klik om te openen

Group Nierkens studies the functional dynamics of the immune system in pediatric cancer patients, in particular in children treated with immune therapy and/or hematopoietic cell transplantation (HCT). The group developed a comprehensive immune monitoring program and performs PK-PD analyses (chemo-, serotherapy and steroids) to make cell transplantation as safe and efficient as possible. Using cord blood as a cell therapy platform, Nierkens and his group generated an efficient protocol for TCR-transduction of cord blood cells for anti-tumor T-cell therapy. Their cord blood-derived dendritic cell vaccine has recently been approved for a phase-I/II in children with AML (U-DANCE trial). 

Research program uitklapper, klik om te openen

Infection and Immunity

Research interests uitklapper, klik om te openen

Hematopoietic Cell Transplantation (HCT)

Immune Therapy

Immune Monitoring

Dendritic cell vaccination

T- cell therapy

PK-PD  

Contact uitklapper, klik om te openen

Stefan Nierkens

Medical Immunologist

Associate Professor Pediatric Tumorimmunology and HCT 

Head Central Immune Monitoring Platform

Email

Phone +31 (0)6 33048039 

Location uitklapper, klik om te openen

Center for Translational Immunology

University Medical Center Utrecht

Heidelberglaan 100, 3584 CX Utrecht. Room F03.818

Related website 

Group members uitklapper, klik om te openen

Group Leader

dr. S. Nierkens 

Associate Professor - medical

Postdocs

Niek van Til

Maud Plantinga

Coco de Koning

Technicians

Denise van den Beemt

Ester Dunnebach

PhD students

Annelisa Cornel, PhD student

Vania LoPresti , PhD student

Celina Szanto, PhD student

Brigitte van den Broek, MD, PhD student

Shanice Beerepoot, MD, PhD student

Julia Mohlman, PhD student

Linde Dekker, PhD student 

Join our group uitklapper, klik om te openen

Students interested in an internship from 6-9 months can contact  Stefan Nierkens

Key Publications uitklapper, klik om te openen

  1. Cord-Blood-Stem-Cell-Derived Conventional Dendritic Cells Specifically Originate from CD115-Expressing Precursors. Plantinga M, de Haar CG, Dünnebach E, van den Beemt DAMH, Bloemenkamp KWM, Mokry M, Boelens JJ, Nierkens S. Cancers (Basel). 2019 Feb 5;11(2). pii: E181. doi: 10.3390/cancers1102018 View
  2. Spel L, Nieuwenhuis J, Haarsma R, Stickel E, Bleijerveld OB, Altelaar M, Boelens JJ, Brummelkamp TR, Nierkens S*, Boes M*. *shared. Nedd4 Binding Protein 1 (N4BP1) and TNFAIP3 Interacting Protein 1 (TNIP1) control MHC-1 display in neuroblastoma. Cancer Res. 2018 Sep 13. pii: canres.0545.2018. doi: 10.1158/0008-5472.CAN-18-0545. View
  3. de Koning C, Gabelich JA, Langenhorst J, Admiraal R, Kuball J, Boelens JJ, Nierkens S. Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. Blood Adv. 2018 Mar 13;2(5):565-574. doi: 10.1182/bloodadvances.2017015487. View
  4. Admiraal R, de Koning C, Lindemans CA, Bierings MB, Wensing AMJ, Versluys AB, Wolfs TFW, Nierkens S*, Boelens JJ*. *shared. Viral Reactivations and Associated Outcomes in Context of Immune Reconstitution after Paediatric Hematopoietic CellTransplantation: a Retrospective Cohort study of Consecutive Patients. J Allergy Clin Immunol. 2017 Apr 7. pii: S0091-6749(17)30571-7. View
  5. Admiraal R, Nierkens S, de Witte M, Petersen E, Fleurke G, Verrest L, Raymakers R, Knibbe C, Minnema M, van Kesteren C, Kuball,J, Boelens JJ. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017 Apr;4(4):e183-e191. View

Collaborations uitklapper, klik om te openen

The Netherlands

Caroline Lindemans, MD/PhD, Princess Máxima Center for Pediatric Oncology, HCT unit, Utrecht

Alwin Huitema, Prof, Pharmacy, UMCU / NKI, Utrecht/Amsterdam

Femke van Wijk, PhD, CTI, UMCU, Utrecht

Linde Meyaard, Prof, CTI, UMCU, Utrecht

Jolanda de Vries, Prof. Radboud UMC, Nijmegen

Jurgen Kuball, MD/PhD, UMCU Hematology, Utrecht

Jan Molenaar, PhD, Princess Máxima Center for Pediatric Oncology, Utrecht

Dannis van Vuurden, Princess Máxima Center for Pediatric Oncology, Utrecht

Michel Zwaan, Prof, Princess Máxima Center for Pediatric Oncology, Utrecht

Ruben van Boxtel, PhD.  Princess Máxima Center for Pediatric Oncology, Utrecht

UK

John Anderson, Prof. UCL, UK

Paul Veys, Prof. GOSH, UK

USA

Jaap Jan Boelens, MSKCC, NY, USA

EuroFlow consortium

Clinical trials uitklapper, klik om te openen

Dutch Ethical Committee approval Phase I/II study on Dendritic cell vaccines in AML

PARACHUTE trial on individualized dosing of ATG

Research implementation in patient care uitklapper, klik om te openen

Implementation of ATG dosing nomogram to achieve optimal exposure in the patient

Implementation of ATG therapeutic drug monitoring in high-risk HCT children 

Funding & Grants uitklapper, klik om te openen

Prizes uitklapper, klik om te openen

Rubicon grant L. Spel (2019)

Eric Hack Publication Award C. de Koning (2018)

Tom Voute Investigator award L. Spel (2016)

Pauline Schaap

In the media uitklapper, klik om te openen

2016 Dec 13: RTL live interview - anti kanker vaccin voor kinderen met acu

2016 Jan 14: "De kennis van nu" - ATC in autologous HCT

2014: Koningin Máxima op bezoek bij Villa Joep - Panel discussion in Stedelijk Museum Amsterdam for Queen Máxima of the Netherlands

UMC news

2019 Apr 2: Stamceltransplantatie vergt behandeling op maat

Bedankt voor uw reactie!

Heeft deze informatie u geholpen?
Graag horen we van u waarom niet, zodat we onze website kunnen verbeteren.

Werken bij het UMC Utrecht

Contact

Afspraken

Praktisch

umcutrecht.nl maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet